Enlivex Ltd. (ENLV)Healthcare | Biotechnology | Ness Ziona, Israel | NasdaqCM
0.86 USD
-0.03
(-3.275%) ⇩
(April 17, 2026, 4 p.m.
EDT)
After hours: 0.86 Short-term: ★★☆☆☆ | Long-term: ★☆☆☆☆ | Dividends: ★★☆☆☆ |
Hot Take | April 19, 2026, 1:02 a.m. EDT
Despite a 'Buy' analyst recommendation and massive treasury gains ($1.23B profit), Enlivex (ENLV) is a high-risk, low-fundamentals nebula stock (Biotech). The tiny market cap ($205M), lack of dividends, and negative forward earnings suggest the current price (~$0.86) is being propped up entirely by one analyst's bullish thesis and speculative call buying. Recent price action shows weak momentum, decoupling from the 200-day average. Investors should beware: this is a speculative play on non-core asset appreciation, not a sustainable operational business. |
| Model | MAE |
|---|---|
| MSTL ✓ | 0.096381 |
| AutoARIMA | 0.116264 |
| AutoETS | 0.116267 |
| AutoTheta | 0.136275 |
Forecast horizon: 45 days | Selected: MSTL
| Forecast Reliability | |
|---|---|
| Score | 61% |
| H-stat | 0.87 |
| Ljung-Box p | 0.000 |
| Jarque-Bera p | 0.007 |
| Excess Kurtosis | 0.68 |
| Attribute | Value |
|---|---|
| Sector | Healthcare |
| Debt to Equity Ratio | 0.033 |
| Market Cap | 205,693,952 |
| Trailing P/E | 0.03 |
| Forward P/E | -1.10 |
| Beta | 1.68 |
| Previous Name | Enlivex Therapeutics Ltd. |
| Website | https://www.enlivex.com |
As of April 19, 2026, 1:02 a.m. EDT: Options data reveals heavily skewed investor positioning. Call premiums are overwhelmingly concentrated in Out-of-The-Money (OTM) strikes (0.8% to 100% OI at OTM), suggesting a speculative bet on a significant price increase, potentially driven by the $2.50 strike being a major call hub. Conversely, put positions from the 2026-05-15 expiration are entirely In-The-Money (ITM) relative to the current price, with significant OTM put volume appearing at the June/August horizon (Vol 22 > OI 60 at $0.50 strike). The distribution shows a bullish 'hope' signal in calls but a defensive or contrarian 'insurance' signal in puts for June onwards, indicating uncertainty about downside support despite the OTM call speculation. IV is low but skewed higher for short-term calls.
| Attribute | Value |
|---|---|
| 52 Week Change | -0.022727251 |
| Address1 | 14 Einstein Street |
| All Time High | 440.0 |
| All Time Low | 0.66 |
| Ask | 1.11 |
| Ask Size | 2 |
| Average Analyst Rating | 2.0 - Buy |
| Average Daily Volume10 Day | 753,710 |
| Average Daily Volume3 Month | 586,735 |
| Average Volume | 586,735 |
| Average Volume10Days | 753,710 |
| Beta | 1.682 |
| Bid | 0.6132 |
| Bid Size | 2 |
| Book Value | 8.151 |
| City | Ness Ziona |
| Compensation As Of Epoch Date | 1,577,750,400 |
| Country | Israel |
| Crypto Tradeable | 0 |
| Currency | USD |
| Current Price | 0.8595 |
| Current Ratio | 193.236 |
| Custom Price Alert Confidence | HIGH |
| Date Short Interest | 1,774,915,200 |
| Day High | 0.9 |
| Day Low | 0.847 |
| Debt To Equity | 0.033 |
| Display Name | Enlivex |
| Dividend Date | 1,551,830,400 |
| Earnings Timestamp End | 1,725,048,000 |
| Earnings Timestamp Start | 1,725,048,000 |
| Ebitda | -14,668,000 |
| Ebitda Margins | 0.0 |
| Enterprise To Ebitda | -13.561 |
| Enterprise Value | 198,915,392 |
| Eps Current Year | -0.59 |
| Eps Forward | -0.78 |
| Eps Trailing Twelve Months | 25.48 |
| Esg Populated | 0 |
| Exchange | NCM |
| Exchange Data Delayed By | 0 |
| Exchange Timezone Name | America/New_York |
| Exchange Timezone Short Name | EDT |
| Fifty Day Average | 1.05158 |
| Fifty Day Average Change | -0.19207996 |
| Fifty Day Average Change Percent | -0.18265845 |
| Fifty Two Week Change Percent | -2.272725 |
| Fifty Two Week High | 2.1 |
| Fifty Two Week High Change | -1.2405 |
| Fifty Two Week High Change Percent | -0.5907143 |
| Fifty Two Week Low | 0.66 |
| Fifty Two Week Low Change | 0.19949996 |
| Fifty Two Week Low Change Percent | 0.30227265 |
| Fifty Two Week Range | 0.66 - 2.1 |
| Financial Currency | USD |
| First Trade Date Milliseconds | 1,406,813,400,000 |
| Float Shares | 54,939,574 |
| Forward Eps | -0.78 |
| Forward P E | -1.1019231 |
| Free Cashflow | -1,737,054,976 |
| Full Exchange Name | NasdaqCM |
| Full Time Employees | 34 |
| Gmt Off Set Milliseconds | -14,400,000 |
| Gross Margins | 0.0 |
| Has Pre Post Market Data | 1 |
| Held Percent Insiders | 0.8658 |
| Held Percent Institutions | 0.00822 |
| Implied Shares Outstanding | 239,318,158 |
| Industry | Biotechnology |
| Industry Disp | Biotechnology |
| Industry Key | biotechnology |
| Is Earnings Date Estimate | 0 |
| Language | en-US |
| Last Fiscal Year End | 1,767,139,200 |
| Last Split Date | 1,551,830,400 |
| Last Split Factor | 1:8 |
| Long Business Summary | Enlivex Ltd., together with its subsidiaries, operates as a clinical-stage macrophage reprogramming immunotherapy company in Israel. It offers AllocetraTM, a cell therapy designed to restore macrophage homeostasis, as well as develops AllocetraTM intra-articular injection for the treatment of knee osteoarthritis, which is in phase 1/2 trial; intra-articular AllocetraTM in osteoarthritis of the temporomandibular joint (TMJ); and Allocetra-OTS for the treatment of organ failure in adult sepsis patients, which is in phase 2. Enlivex Ltd. was formerly known as Enlivex Therapeutics Ltd. and changed its name to Enlivex Ltd. in February 2026. The company was founded in 2005 and is headquartered in Ness Ziona, Israel. |
| Long Name | Enlivex Ltd. |
| Market | us_market |
| Market Cap | 205,693,952 |
| Market State | CLOSED |
| Max Age | 86,400 |
| Message Board Id | finmb_84011067 |
| Most Recent Quarter | 1,767,139,200 |
| Name Change Date | 2,026-04-19 |
| Net Income To Common | 1,235,527,936 |
| Next Fiscal Year End | 1,798,675,200 |
| Non Diluted Market Cap | 205,789,684 |
| Number Of Analyst Opinions | 1 |
| Open | 0.876 |
| Operating Cashflow | -10,416,000 |
| Operating Margins | 0.0 |
| Payout Ratio | 0.0 |
| Phone | 972 2 620 8072 |
| Post Market Change | 0.0 |
| Post Market Change Percent | 0.0 |
| Post Market Price | 0.8595 |
| Post Market Time | 1,776,468,952 |
| Prev Name | Enlivex Therapeutics Ltd. |
| Previous Close | 0.8886 |
| Price Eps Current Year | -1.4567797 |
| Price Hint | 4 |
| Price To Book | 0.10544718 |
| Profit Margins | 0.0 |
| Quick Ratio | 0.694 |
| Quote Source Name | Nasdaq Real Time Price |
| Quote Type | EQUITY |
| Recommendation Key | buy |
| Recommendation Mean | 2.0 |
| Region | US |
| Regular Market Change | -0.0291 |
| Regular Market Change Percent | -3.27481 |
| Regular Market Day High | 0.9 |
| Regular Market Day Low | 0.847 |
| Regular Market Day Range | 0.847 - 0.9 |
| Regular Market Open | 0.876 |
| Regular Market Previous Close | 0.8886 |
| Regular Market Price | 0.8595 |
| Regular Market Time | 1,776,456,001 |
| Regular Market Volume | 406,098 |
| Return On Assets | -0.00796 |
| Return On Equity | 1.26168 |
| Sand P52 Week Change | 0.38150132 |
| Sector | Healthcare |
| Sector Disp | Healthcare |
| Sector Key | healthcare |
| Shares Outstanding | 239,318,158 |
| Shares Percent Shares Out | 0.0022 |
| Shares Short | 535,106 |
| Shares Short Previous Month Date | 1,772,150,400 |
| Shares Short Prior Month | 563,947 |
| Short Name | Enlivex Ltd. |
| Short Percent Of Float | 0.0022 |
| Short Ratio | 0.68 |
| Source Interval | 15 |
| Symbol | ENLV |
| Target High Price | 20.0 |
| Target Low Price | 20.0 |
| Target Mean Price | 20.0 |
| Target Median Price | 20.0 |
| Total Cash | 5,755,000 |
| Total Cash Per Share | 0.024 |
| Total Debt | 641,000 |
| Tradeable | 0 |
| Trailing Annual Dividend Rate | 0.0 |
| Trailing Annual Dividend Yield | 0.0 |
| Trailing Eps | 25.48 |
| Trailing P E | 0.03373234 |
| Trailing Peg Ratio | None |
| Triggerable | 1 |
| Two Hundred Day Average | 1.0721 |
| Two Hundred Day Average Change | -0.21260005 |
| Two Hundred Day Average Change Percent | -0.19830243 |
| Type Disp | Equity |
| Volume | 406,098 |
| Website | https://www.enlivex.com |
| Zip | 7,403,618 |